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Health-related quality of life (HRQL) and economic burden are important issues for people
with sickle cell disease (SCD) owing to better survival due to medical advances. Preference-
based or utility information is necessary to make informed economic decisions on treatment
and alternative therapies. This study aimed to assess preference-based measures of HRQL
in sickle cell patients.
Methods and findings
Data were collected from two SCD outpatient clinics in Ibadan, Nigeria. A standard algorithm
was used to derive utility scores, and measure SF-6D from the SF-36. A multivariate
regression model was used to assess predictors and their impact. A combination of socio-
demographic, bio-physiological and psychosocial variables predicted utility score in people
with SCD. Socio-demographic and bio-physiological factors explained 7.5% and 17.9%
of the variance respectively, while psychosocial factors explained 4.9%. Women had
lower utility scores with a small effect size (d = 0.17). Utility score increased with level of edu-
cation but decreased with age, anxiety, frequency of pain episodes and number of co-
morbidities.
Conclusions
Utility score in SCD was low indicating a substantial impact of the disease on HRQL of
patients and the value they place on their health state due to the limitations they experi-
enced. Interventions should include both clinical and psychosocial approach to help in
improving their quality of life of the patients.
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Introduction
Worldwide, approximately 1,000 children are born daily with sickle cell disease[1–3]. The dis-
ease is the most common genetic disease in sub-Saharan Africa accounting for over 5% of
under-five mortality in Africa [2,4,5]. The clinical manifestation of SCD range from mild to
very severe symptoms across the ages. Genotype, the volume of foetal haemoglobin (HbF) and
comorbidities have been suggested as factors responsible for degree of severity[6–10]. Some of
the acute and chronic clinical manifestations include painful crisis, vaso-occlusive episodes,
stroke, anaemia, hand-foot syndrome, jaundice, frequent infections, delayed growth, vision
problems, aplastic crisis, acute chest syndrome, leg ulcers, priapism, pulmonary hypertension
and organ damage [9,11–16]. Though survival has increased in the last four decades such that
people with SCD can now live into the fifth decade of life [17–20], the impact on the HRQL of
the affected individual is substantial[21–23]. Consequently, studies have recognised the impor-
tance of HRQL and cost-effectiveness of interventions as outcome measures in addition to sur-
vival and morbidity [24].
The common and widely accepted means of measuring HRQL is through psychometric,
non-preference-based, methods. Such methods do not provide utilities to assess preferences of
the patient or to carry out cost-effectiveness analysis of therapy.While non-preference-based
methods have been used to investigate HRQL in SCD[23,25–28], preference-based studies
have been lacking. Non-preference-based methods focus on functions in the domains of health
assessed, while preference-based or utility measures explore how patients (or the general popu-
lation) value experiencing a given health state that is defined by functioning and well-being in
those domains. The utility approach focuses on the respondents’ valuations of their (health)
states whereby outcomes are measured in terms of the preferences that individuals express for
being in particular states. The measures combine a descriptive component with the respective
valuation component, where the valuation part reflects the values that a society attaches to dif-
ferent health states[29]. While non-preference-based measures aim to measure health (or
change in health) perceived by individuals, the objective of a utility measure is to value health
states[29].
Quality-of-life measures provide ratings or rankings of health and life[30]. Utility measures
move the measurement of quality of life from rankings to judgments of the worth or value of
life with a given state of health. The utility approach to healthcare is based on modern utility
theory–a model of rational decision-making under uncertainty as posited by von Neuman and
Morgenstern [31]. They argued that utilities are indicators of an individual’s preference for
particular outcomes or health state under conditions of uncertainty. It has been suggested that
the utility approach is a viable alternative for investigators to use in measuring health-related
quality of life [32,33].
Utility measures provide single scores across domains of health that range from 0 to 1,
(0 =“dead”, and 1 = “perfect health”). A single utility score is important for a variety of reasons
one of which is to assess cost effectiveness of interventions with the aim of making informed
decisions on the use of healthcare resources [24]. In addition, utility can be used to compare
different therapies, such as in comparative effectiveness research[34]. For example, an inter-
vention that produces a difference in utility of 0.03–0.04 is of clinical importance[35] because
utilities attach numerical value to the strength of individual, population or society preference
for different health outcomes[36]. Furthermore, utility can be used to measure overall health
impact to aid decision making. Moreover, utility scores can be combined with life-expectancy
estimates to obtain the quality-adjusted life years (QALYs) which is useful for economic evalu-
ations of cost and effectiveness. Health economic analysis of new medical interventions require
preference-based weighted measures of quality of life utilities to estimate QALYs[37]. QALYs
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are valuable in economic evaluations because they incorporate the gained life years as well as
the quality of life years to enhance informed decision making. QALYs are the preferred out-
come in cost-effectiveness studies which enables comparisons between treatment alternatives
[38].
Moreover, utility values are useful in quantifying signs and symptoms related to healthcare,
and desirability of a particular disease state according to how a patient perceives his or her life
[39,40]. This is useful in evidence-based medicine where best clinical decision-making is a
product of high quality clinical research, clinician’s expertise and experience and the patient’s
values, desires and perspectives[41]. Furthermore, the efficacy of a medical intervention in
improving patient quality of life can be measured by examining improvement in utility values
[42].
Utilities are intended for use in any population or disease group [43] and thusare relevant
in SCD. However, to our knowledge studies on determinants of utilities in SCD have been
lacking in existing literature. Anie et al [36] examined the relationship between self-reported
pain, mood and utility in adults with SCD during and after hospital admission. In contrast,
our study examined biological, psychosocial and sociodemographic determinants of utilities in
adults with SCD who visited hospital for routine medical appointments. The aims of this study
therefore were (1) to describe HRQL using a preference-based approach in SCD patients in
Nigeria and (2) to investigate socio-demographic, bio-physiological and psychosocial predic-
tors of utility score in the study population. The results can be used to compare the burden of




Data for this cross-sectional study were collected at the outpatient units of two sickle cell clin-
ics in Ibadan, the University College Hospital (UCH) and Adeoyo General Hospital. We used
a convenience sampling method whereby participants were recruited as they arrived at the
clinics. The purpose of the research was explained to them and were told of their rights to par-
ticipate or to withdraw at anytime during the exercise. They were given informed consent
forms to read and sign if they agreed to participate. Respondents were made up of 200 adults
diagnosed with SCD, aged 18 years and older (see Table 1).
Ethical approval
The Ethics Board of the University of Ibadan/University College Hospital Ethics Committee
and the Research Ethics Committee of the University of Sunderland granted approval for this
study.
Instruments
A personal information questionnaire was administered along with other instruments such as
the SF-36, GAD-7 and PHQ-9. The personal information questionnaire was designed to elicit
information on socio-demographic variables and self-report of hospitalisation, blood transfu-
sion, pain episodes in the last six months and co-morbidities. Self-reports of co-morbidities
tend to be accurate, and therefore represent a reliable and valid measure of actual co-morbidity
[44–47]. Eleven co-morbidities related to SCD identified in literature[48–52] were specified in
this instrument. They were asthma, arthritis, diabetes, epilepsy, heart disease, high blood pres-
sure, leg ulcers, lung disease, pneumonia, priapism and stroke. Participants were asked to
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Married 41 20.5
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Not employed 43 21.5
Income level
Below minimum wage 167 83.5
�Minimum wage 33 15.5
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Living alone 18 9
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High blood pressure 16 8%
Leg ulcers 25 12.50%
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indicate which of these they had or had been informed by their doctors that they had. Partici-
pants were also asked to mention any other diseases they had that were not listed. The co-mor-
bidities were scored for individual respondents (1–12) depending on number of
comorbidities. This was re-coded as 0, 1–2, and 3 or more to reduce skewness in the
distribution.
Assessment of Utility: Utility could be derived through the direct method which consists of
eliciting information from individuals through rating scale (RS), standard gamble (SG) or time
trade-off (TTO) techniques. The indirect approach uses multi-attribute utility scales. This
involves the use of a questionnaire. Individuals complete the questionnaire to describe their
health state, these descriptions are converted to index scores using societal valuations. Health
state valuations are normally derived from a representative sample of the general population
[53]
This study employed the indirect method whereby individuals completed questionnaires to
describe health scale which are then converted to index scores using social valuations [43]. The
Short Form (SF-36) version 1 health survey [54]is a widely used general HRQL measure which
has been validated across a wide variety of age, race, disease populations including SCD with
acceptable psychometric properties [25,55–59]. The SF-36 contains 36 questions aggregated
into 8 domains namely physical function, role limitation, social function, bodily pain, mental
health and vitality, role physical and general health. These domains are summarised into two
health components, the Physical Component scores (PCS) and the Mental Component score
(MCS). The utility measure, SF-6D was derived from 11 of the 36 questions of the SF-36
instrument which include six dimensions (physical function, role limitation, social function,
bodily pain, mental health and vitality) that defined 18,000 health states [60]. The scoring algo-
rithm to derive SF-6D from SF-36[61–63]was requested and obtained from Sheffield Univer-
sity (http://www.sheffield.ac.uk/scharr/sections/heds/mvh/noncommercial).The algorithm
used preference weights obtained from a sample of the UK general population to generate the
SF-6D utility score in the UK population. Utility scores ranged from 0.3 to 1.00 where 1.00 rep-
resents “full health”.[64]. The psychometric properties of SF-6D have been investigated and
reported to be acceptable[43].
Assessment of anxiety: We used the generalised anxiety disorder (GAD-7) instrument to
measure anxiety in the population. GAD-7[65]is a 7-item scale developed for screening gener-
alised anxiety disorder in line with the Diagnostic and Statistical Manual of Mental Disorders
Fourth Edition (DSM-IV)[66] diagnoses. Respondents were asked to rate their experience in
the last two weeks with respect to how they were bothered by symptoms of anxiety. Rating
options were ‘not at all’, ‘several days’, ‘more than half the days’, ‘nearly every day’. The ratings
were allocated scores of 0,1,2,3 respectively. The GAD-7 total score ranges from 0 to 21. Cut
points of 5, 10, and 15 were interpreted as representing mild, moderate and severe levels of
anxiety. The instrument has good psychometric properties [65] and has been used to measure
anxiety in SCD populations in Brazil [67] and the USA [68].
Assessment of depression: The Patient Health Questionnaire (PHQ) was used to assess
depression in the population. The PHQ-9[69] is a subscale of the PHQ designed to assess
depression in patients. The instrument has been established to be reliable and valid instrument
for screening depressive disorder according to the DSM-IV diagnoses [69]. Patients were
asked to rate how often they had been bothered by each of the depressive symptoms in the last
two weeks. Experiences were rated from 0, ‘not at all’ to 3, ‘nearly every day’. The total possible
score ranges from 0 to 27. Symptoms of depression were assumed to be minimal for score < 5,
mild = 5–9, moderate = 10–14, and severe,�15 [70]. PHQ-9 has been shown to be equal or
superior to other measures of depression [71–73]. The psychometric properties of PHQ-9
have been well documented [70] and have been used in measuring depression in SCD
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[67,68,74,75]. Items left blank (missing data) were filled with the mean scores of the completed
items provided missing items were less than 20%, otherwise the item was treated as completely
missing for the individual; this approach was considered to have a lower risk of missing per-
sons with depression, anxiety or somatisation [70]. However, no item or respondent in this
study had up to 20% missing values.
Assessment of pain and hospital admissions: The measures were made up of events in the
life of the participants in the last six months prior to data collection. Participants were asked to
indicate the number of times they have been admitted into the hospital in the last 6 months on
a scale of 0 (none) to 4 (more than three times). In the same vein, they were asked to state how
many times they had had pain episodes in the last 6 months on the same scale.
Reliability: Though the psychometric properties of these instruments have been established
in different studies, populations and countries, However, researchers have suggested that
investigators should not rely on published reliability estimates because alpha is a property
obtained from a specific sample of the population being tested [76,77]. Reliability was investi-
gated using the Cronbach alpha [78].
Statistical analysis
Statistical analyses were performed using SPSS version 24 (SPSS, Inc., Chicago). Descriptive
statistics were computed for all the variables. Means and standard deviations were obtained for
continuous variables, and frequencies and percentages for the categorical variables. Utility
scores were presented as mean values, standard deviations (SD) and 95% confidence interval
(CI). The Shapiro-Wilk test indicated that the utility score distribution in the population was
normal (Shapiro-Wilk = 0.994, p = 0.601). We also report utility score stratified by socio-
demographic variables. Student’s t-test was used to compare utility between two independent
variables and one-way analysis of variance (ANOVA) with post-hoc analysis was used in vari-
ables with more than two categories. We examined the collinearity statistics to identify possible
presence of multi-collinearity. The Tolerance statistic (range 0.36–0.93) and the variance infla-
tion factor (VIF, range 1.1–4.5) statistic showed that multi-collinearity was not present among
the independent variables. Possible associations between utility score and other variables was
investigated using bivariate correlation. A hierarchical regression was used to test predictors.
The independent variables were selected based on previous studies [27,48,79–81]. The vari-
ables were entered in three blocks based on order employed in similar studies [82,83]. The first
block was made up of socio-demographic variables namely age, gender, marital status, educa-
tion, employment and income. The second block consisted of biological variables such as
genotype, number of co-morbidities, frequency of pain episode and hospital admission. The
third block included psychosocial variables, namely anxiety and depression. Statistical signifi-
cance was set at 5%. To measure substantive significance, we calculated and classified effect
sizes as small (0.3), medium (0.5) or large (0.8) according to Cohen’s recommendation [84].
The 95% confidence interval (CI) was also computed for variables of interest.
Results
The mean age of participants was 27.9 years (SD: 6.95) with 58.5% of them female (see
Table 1). Single participants or Never married constituted 75.5% of the sample, while 20.5%
were married, with 4% either divorced or widowed. Eighty-five percent of the participants had
the HbSS genotype while 15% were HbSC. There was no Hb thalassemia in the population.
The educational profile showed only 9.5% had below secondary education and 42.2% have ter-
tiary education. Only 36% indicated that they had full time or part time employment and
about 93% were either living with relatives or friends. Most of the participants reported that
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they have confidants (85.5%) and 19% percent have children. About one-third (32.5%) of the
participants indicated that they had been diagnosed with co-morbidities. The most prevalent
co-morbidity was leg ulcers (12.5%) followed by priapism (8.5%) and high blood pressure
(8%). Other identified co-morbidities were mostly pain-related, rheumatism, chest pain and
back pain.
Sample characteristics
The means, standard deviations and confidence intervals of variables for SF-6D, GAD-7 and
PHQ-9 were calculated (Table 2). The mean utility score in the population was 0.65 (SD: 0.12;
range: 0.310–0.965). The reliabilities of GAD-7 and PHQ-9 were acceptable, (Cronbach- α,
0.90 and 0.82, respectively). The mean anxiety in the population was minimal (GAD-7 < 5)
while depression was mild (5<PHQ-9 < 10). A frequency analysis showed that 12% had mod-
erate to severe anxiety while 19% had moderate to severe depression.
The utility score was lower for those who had co-morbidities than those who did not (see
Table 3); this difference was statistically significant (p = 0.001) with an effect size of 0.63.
Female gender also had lower utility score but not statistically significant (p = 0.179). There
were more patients with HbSS than HbSC genotypes but the difference in their utility scores
was not statistically significant (p = 0.894). Those living alone reported lower utility than those
living with others such as relatives or friends and thus probably enjoyed support, however this
difference was not statistically significant (p = 0.227).
Bivariate relationships
The correlation analysis revealed that utility values decreased with an increase in number of
co-morbidities (r = -0.32, p<0.001), depression (-0.34, p<0.001), anxiety (r = -0.42, p<0.001,
pain frequency (r = -0.31, p<0.001) and hospital admission (r = -0.16, p<0.026) but exhibited
a positive relationship with level of education (r = 0.14, p = 0.049). The association with age
was positive but not statistically significant (r = 0.14, p = 0.054).
Multivariate analysis
All the independent variables explained 30.3% of the variation (see Table 4). The socio-
demographic factors alone accounted for 7.5%, the predictors were age, education and
employment. This increased to 25.4% when the bio-physiological variables were added.
Frequency of pain, number of co-morbidities, age and level of education were associated with
utility score. Psychosocial variables accounted for an additional 4.9% where anxiety was nega-
tively associated with health utility. Increase in anxiety, frequency of pain and number of co-
morbidities led to a reduced utility value while higher level of education positively predicted
utility score.
Table 2. Descriptive analysis.
Instruments Variable Mean SD 95% CI Reliability
SF-6D (Derived from SF-36) Utility 0.65 0.12 0.63–0.67
GAD-7 Anxiety 3.86 3.91 3.32–4.40 0.902
PHQ-9 Depression 5.14 4.70 4.49–5.79 0.824
Questionnaire
Pain frequency 2.37 1.19 2.20–2.53
Hospital admission 1.495 1.147 1.34–1.66
https://doi.org/10.1371/journal.pone.0223043.t002
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Discussion
Health utilities are designed to investigate HRQL across domains of health to provide a single
score that incorporates how patients’ (or the general population) value experiencing a given
health state that is defined by level of functioning and well-being in those domains. While the
source of the values used to initially develop these measures was the general population, such
scores are important to measure the burden of diseases. The mean utility score for SCD
patients, in our study, (0.65±0.12) compares with the utility score (0.66± 0.26) reported for
people with haemochromatosis [85] and (0.66±0.14) reported for people with age-related mac-
ular degeneration[86] but much lower than the utility score (0.75±0.14) reported in adults
with type 1 diabetes [87], and that for overweight and obese women with urinary incontinence
(0.75±0.10) [88], and those with chronic kidney disease (0.67±0.13)[89].Anie et al, [36]
reported a utility score of 0.39±0.40 for SCD patients on admission for pain which improved
to 0.65±0.29 which is similar to our result. Lower utility values indicate that SCD can substan-
tially diminish the HRQL of the affected individual. However, these comparisons should be
interpreted with caution as the studies used different methods to derive their respective utility
Table 3. Group differences and effects sizes.
Groups N Mean SD t-value df 95% CI p-value Cohen’s (d)
Gender
Male 83 0.66 0.11 1.35 198 0.64–0.69 0.179 0.17
Female 117 0.64 0.12 0.62–0.66
Living situation
Alone 18 0.62 0.08 1.213 198 0.58–0.65 0.227 0.3
With others 182 0.65 0.12 0.64–0.67
Confidants
Yes 171 0.651 0.11 0.137 198 0.60–0.70 0.891 0.02
No 29 0.647 0.13 0.63–0.67
Genotype
SS 170 0.651 0.12 0.133 198 0.63–0.67 0.894 0.03
SC 30 0.648 0.12 0.61–0.69
Co-morbidity
No 135 0.67 0.12 4.338�� 198 0.65–0.69 <0.001 0.63
Yes 65 0.6 0.1 0.58–0.63
Groups N Mean SD F-value df 95% CI p-value Cohen’s (d)
Marital Status 1.141 197 0.322 0.12
Never married 151 0.66 0.12 0.64–0.68
Married 41 0.63 0.09 0.61–0.66
Others (divorced, separated, widowed) 8 0.61 0.12 0.53–0.69
Education 2.415 197 0.092 0.16
� Primary 19 0.6 0.12 0.55–0.65
Secondary 97 0.65 0.11 0.63–0.67
Post-secondary 84 0.66 0.12 0.64–0.67
Employment 0.313 197 0.732 0.06
Full-Time 43 0.66 0.11 0.63–0.67
Part-time 30 0.64 0.1 0.60–0.68
Not employed 127 0.65 0.12 0.63–0.70
�� p< 0.01
https://doi.org/10.1371/journal.pone.0223043.t003
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score. For example, the study on haemochromatosis[85] used the Assessment of Quality of life
4D(AQOLD-4D), the study by Anie et al[36] used the EuroQol EQ-5D.
The lower utility scores in women than men found in this study might not be statistically
significant, more information is needed to establish if this difference is of clinical importance.
Similar conclusion may be applicable to the difference between those living alone and those
living with others as it has been suggested that a difference of 0.03 could be clinically important
[90,91]. The finding of a significant difference between those who had at least one co-morbid-
ity compared to those who had none is worthy of comment. SCD patients are a vulnerable,
Table 4. Predictors of health utility score.
Variables BUnstandardized SE (B) B Standardized Statistic (t) p-value R Sqrd F-change Sig. F-change
Block 1 2.598��� 0.019 0.075 2.598 0.019
Constant 0.596 0.057 10.515 0.000
Age -0.033 0.015 -0.169� -2.416 0.033
Gender -0.021 0.017 -0.091 -1.295 0.197
Marital-status 0.003 0.017 0.015 -0.186 0.853
Education 0.035 0.013 0.193�� 2.632 0.009
Employment 0.042 0.02 0.294� 2.131 0.034
Income -0.036 0.022 -0.237 -1.671 0.096
Block 2 6.45 0 0.254 11.389 < 0.001
Constant 0.655 0.058 11.383 0
Age -0.031 0.015 -0.159� -2.139 0.034
Gender -0.01 0.015 -0.044 -0.683 0.496
Marital-status -0.003 0.015 -0.014 -0.179 0.858
Education 0.048 0.012 0.263�� 3.895 0
Employment 0.022 0.018 0.158 1.242 0.216
Income -0.012 0.02 -0.079 -0.606 0.545
Genotype 0.009 0.021 0.029 0.441 0.66
Hospital_admission -0.006 0.007 -0.059 -0.873 0.384
Pain-frequency -0.027 0.007 -0.280�� -4.186 0
Num-co-morbidity -0.05 0.013 -0.272�� -3.853 0
Block 3 6.76 0 0.303 9.407 <0.001
Constant 0.707 0.058 12.212 0
Age -0.023 0.014 -0.118 -1.611 0.109
Gender -0.006 0.015 -0.025 -0.397 0.692
Marital-status -0.008 0.015 -0.039 -0.52 0.603
Education 0.044 0.012 0.241�� 3.645 0
Employment 0.027 0.018 0.189 1.509 0.133
Income -0.017 0.02 -0.11 -0.849 0.397
Genotype 0.002 0.021 0.007 0.108 0.914
Hospital_admmission -0.002 0.007 -0.016 -0.24 0.811
Pain-frequency -0.028 0.006 -0.284�� -4.368 0
Num-co-morbidity Anxiety -0.029 0.014 -0.156� -1.997 0.047
Depression -0.037 0.014 -0.229� -2.604 0.01
-0.005 0.011 -0.043 -0.481 0.631
�P<0.05
�� P<0.01
��� = F statistic
https://doi.org/10.1371/journal.pone.0223043.t004
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chronically ill population with a high prevalence of co-morbidities which contributed to
reduced quality of life in chronic diseases[92].
Age was negatively associated with utility, as expected, because SCD patients are exposed to
increased clinical complications as they grow older.This supports findings from a general UK
population where utility score was reported to decrease as age increased[93]due to age-depen-
dent end-organ dysfunction associated with the disease. Before we entered the psychosocial
variables into the regression model, age was a significant predictor of utility score, however,
the statistical significance disappeared when anxiety and depression were added into the
model. We do not know whether age is a confounder in this study especially because a positive
relationship was found between age and anxiety. The negative associations of anxiety and
depression with health utility found in this study, support previous studies where these vari-
ables were reported to associate negatively with HRQL in SCD[67,81,94,95]. The multivariate
regression modelling showed that pain frequency, anxiety, number of co-morbidities and edu-
cation were strong predictors of health utility score. In terms of the direction of effects, these
impacts were as expected. For example, anxiety included items that measure mental health
while pain has been presented as the hallmark of SCD[36,96,97] and is responsible for emer-
gency visits [96]. Therefore, their increase or severity was found to associate with decreased
utility score. This is a pointer to the need to approach clinical management of SCD taking a
multidisciplinary perspective so as to ensure better quality of life for the patients. For example,
in addition to interventions that focus on biological and physiological variables, routine inves-
tigation of patients’ psychiatric status should be integrated into the disease management
protocol.
Clinical implications
Table 4 shows that the beta coefficients ranged between -0.01 and 0.04 on the 0–1 health utility
score. According to Walters and Brazier[90], the minimally important difference ranges
between 0.01 and 0.05 with a weighted average of 0.03. Khanna[91] also reported a minimally
important difference of 0.03 in systemic sclerosis. All the predictors had the unstandardized
beta coefficients with absolute values equal or greater than 0.03 indicating that beyond statisti-
cal significance, they may be of clinical importance in the management of SCD as well as to
enhance the utility score measure of health-related quality of life. However, more information
is needed to establish this assertion.
Limitations
Owing to the cross-sectional nature of the design it was not possible to definitively establish a
causal relationship. Also, the study relied on self-reported co-morbid conditions, although pre-
vious studies have established high agreement between self-reported co-morbidities and medi-
cal records abstractions [44–47,98]. The authors did not examine medical records to validate
patients’ reports of their hospital admissions and pain episodes which could be understated or
overstated due to recall errors. SF-6D has been reported to have a floor effect and different der-
ivations of utility measures have been reported to yield different results [87,99]. However, SF-
6D has been reported to be relatively better in discriminating between health states [87,100].
Our analysis was based on preference weights derived from the UK population because such
weighs do not exist in the local population, We are therefore cautious in our interpretations
because the standard of living, access to medical facilities and life expectancy are better in the
UK. This work could be replicated using different preference-based measures. Further
research could also include a longitudinal study of utility in people with SCD using both direct
and derived methods. There is also the need to compare direct and derived methods in SCD as
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well as a comparison of the performance of the different derivation like SF-6D, EQ-5D, HUI3
and so on.
Conclusion
Health utilities are important values necessary to understand the preferences of an individual
for different health outcomes and when combined with survival estimates can be employed in
cost utility analysis of medical treatment. Study of health utilities has been lacking in SCD,
therefore our findings provide an important contribution to knowledge. This study has shown
that utility decreases with age, increasing co-morbidities, painful episodes and anxiety;a multi-
disciplinary approach is therefore required in the management of the disease. In addition, clin-
ical interventions to ameliorate the painful episodic exacerbations of SCD patients and to
manage the disease should also consider the influence of co-morbid conditions. The present
study suggests that level of education predicted better utility, although there is need for further
studies to establish this relationship as there could be other factors influencing this relation-
ship. It is however recommended that SCD patients, especially in sub-Saharan Africa should
be encouraged to enrol in open and distance learning programmes which gives them the
opportunity to study at their own pace. As SCD affects schooling, educational policy could be
designed to give better opportunities to people with SCD; we believe this could potentially
enhance their quality of life.
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